The authors review a House Oversight Committee investigation report on AbbVie’s practices pertaining to adalimumab (Humira) to shed light on broader pharmaceutical market dynamics hindering a competitive market.
Micaela Laber, MPH, MBA
Advertisement
Articles by Micaela Laber, MPH, MBA
Advertisement
Latest Updated Articles
- Humira: The First $20 Billion Drug
Published: February 8th 2023 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
Prescription Access Crisis: 40% of GLP-1 RA Rx Are Unfilled
2
Experts, Patients Highlight Barriers to Arthritis Care Amid World Arthritis Day Observance
3
FDA Expands Upadacitinib Label for Treating Inflammatory Bowel Disease
4
Medical School Diversity Declines Following Affirmative Action Repeal
5
